Croácia - croata - HALMED (Agencija za lijekove i medicinske proizvode)

roche d.o.o. ulica grada vukovara 269 a 10000 zagreb -

União Europeia - croata - EMA (European Medicines Agency)

accord healthcare s.l.u. - eptifibatid - infarkt miokarda - antitrombotska sredstva - eptifibatidni sporazum namijenjen je upotrebi s acetilsalicilnom kiselinom i nefrakcioniranim heparinom. Ламифибана akord je indiciran za prevenciju ranog infarkta miokarda kod odraslih bolesnika nestabilnom anginom i ne-q-инфарктом miokarda, s posljednja epizoda bol u prsima javlja u roku od 24 sata электрокардиограммой (ekg) izmjene i/ili povišene razine enzima кардиоспецифических. pacijentu je vjerojatno da će imati koristi od Ламифибана liječenje pristanak onih visok rizik od razvoja infarkta miokarda u prvih 3-4 dana nakon pojave akutnih simptoma angine uključujući, na primjer one koje se mogu proći u početku ptca (чрескожная Транслюминальная koronarna angioplastika endovaskularno).

União Europeia - croata - EMA (European Medicines Agency)

ge healthcare as  - regadenoson - miokardijalni perfuzijski imaging - srčana terapija - ovaj je lijek samo za dijagnostičku uporabu. tvrtka rapiscan je selektivna koronarna вазодилататор za korištenje kao farmakološki stres-agent радионуклидная vizualizacija perfuzije miokarda (ВПМ) kod odraslih pacijenata, koji ne može proći adekvatnu fizičku teret.

União Europeia - croata - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

União Europeia - croata - EMA (European Medicines Agency)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.

Montenegro - croata - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, promet roba i usluga, export - import "pharmaline" d.o.o. podgorica - enoksaparin natrijum - rastvor za injekciju u napunjenom injekcionom špricu - 2000i.j.(20mg)/0.2ml

Montenegro - croata - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, promet roba i usluga, export - import "pharmaline" d.o.o. podgorica - enoksaparin natrijum - rastvor za injekciju u napunjenom injekcionom špricu - 2000i.j.(20mg)/0.2ml

Montenegro - croata - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, promet roba i usluga, export - import "pharmaline" d.o.o. podgorica - enoksaparin natrijum - rastvor za injekciju u napunjenom injekcionom špricu - 6000i.j.(60mg)/0.6ml

Montenegro - croata - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, promet roba i usluga, export - import "pharmaline" d.o.o. podgorica - enoksaparin natrijum - rastvor za injekciju u napunjenom injekcionom špricu - 4000i.j.(40mg)/0.4ml

Montenegro - croata - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, promet roba i usluga, export - import "pharmaline" d.o.o. podgorica - enoksaparin natrijum - rastvor za injekciju u napunjenom injekcionom špricu - 6000i.j.(60mg)/0.6ml